NASDAQ$AYTU
Aytu BioScience Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Aytu BioPharma's revenue increased and strategic priorities were outlined.
Aytu BioPharma reported a 79% year-over-year increase in net revenue to $24.2 million for the third quarter of fiscal year 2022, marking the highest revenue in the company's history. The company's strategic priorities are focused on driving revenue growth, increasing financial efficiencies, and advancing its pipeline of therapeutics.
- Net revenue increased 79% year-over-year to $24.2 million, the highest in company history.
- Prescription sales grew over 170% year-over-year, reaching $13.9 million.
- Consumer health franchise revenue increased over 23% year-over-year to $10.3 million.
- Gross profit increased to $12.7 million, compared to $(0.5) million in the same quarter last year.
Headline financials
Revenue & EPS history
Aytu BioScience · Revenue · Quarterly
$24.1M
Revenue by segment
Aytu BioScience · $210K total across 1 segment · Q4 2023
- Other$210K-42.6%100.0%
Forward guidance
Aytu BioPharma is focused on driving revenue growth, increasing financial efficiencies, and preparing its pipeline for long-term value creation.
Tailwinds
- Drive revenue growth with the company’s Rx product franchise and consumer health products.
- Enhance its financial performance through operational and manufacturing efficiencies and portfolio prioritization
- Advance and expand a pipeline focused on rare and complex disorders
- Improve gross margins for its ADHD product franchise through transfer of manufacturing to a well-established, global commercial manufacturing organization, a transition that is expected to occur in mid calendar 2023.
- Continue to advance AR101 and Healight programs, which are aimed at treating life-threatening conditions for which there are no or very few available treatment options.
Headwinds
- The company has undertaken an effort to further prioritize its portfolio and operations, which include the divestiture or discontinuation of non-core, unprofitable products, including Cefaclor, Flexichamber, Tuzistra XR, generic Tussionex, and Zolpimist.
- These products produced negative contribution margin, consumed internal resources and incurred expenses, and will be removed from the portfolio.
- AR101 pivotal trial is expected to begin enrolling patients by early 2023.
- The company’s e-commerce health revenue grew 63% in year-over-year YTD
- Aytu expects to improve gross margins on our ADHD products by 15% or more.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-1.0%
Avg return
Earnings day
-4.9%
Avg return
5 days after
-7.0%
Avg return
30 days after
19%
12 / 64 earnings
Positive
+91.7%
Q3 2025
Best reaction
-31.0%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -0.4% | -9.7% | -4.9% | |
| Q2 2026 | -3.3% | -11.8% | -4.4% | |
| Q1 2026 | -13.1% | -2.9% | +11.7% | |
| Q4 2025 | -20.1% | -31.9% | -9.6% | |
| Q3 2025 | +91.7% | +50.4% | +44.4% | |
| Q2 2025 | -0.7% | +0.7% | -13.7% | |
| Q1 2025 | -10.9% | -8.0% | -17.2% | |
| Q4 2024 | -2.9% | -3.3% | -11.1% | |
| Q3 2024 | -10.8% | -7.2% | -14.2% | |
| Q2 2024 | +4.3% | +6.0% | -4.0% | |
| Q1 2024 | -14.2% | -14.2% | +6.7% | |
| Q4 2023 | +61.8% | +76.4% | +60.6% | |
| Q3 2023 | -12.8% | -16.6% | -24.2% | |
| Q2 2023 | -5.1% | -9.9% | -29.8% | |
| Q1 2023 | +5.3% | +21.1% | +10.5% | |
| Q4 2022 | +0.0% | +0.0% | -10.5% | |
| Q3 2022 | +5.8% | +7.7% | -5.8% | |
| Q2 2022 | +5.6% | +4.8% | -13.5% | |
| Q1 2022 | -10.5% | -18.2% | -36.0% | |
| Q4 2021 | -3.7% | -0.7% | -19.9% | |
| Q3 2021 | +0.7% | +5.0% | -5.9% | |
| Q2 2021 | -5.3% | -9.0% | -5.1% | |
| Q1 2021 | -4.9% | -8.8% | -38.4% | |
| Q4 2020 | -14.1% | -16.3% | -23.0% | |
| Q3 2020 | -7.7% | -13.0% | -13.0% | |
| Q2 2020 | +2.6% | +2.6% | +49.4% | |
| Q1 2020 | -21.7% | -28.3% | -14.2% | |
| Q4 2019 | -10.9% | -16.7% | -18.8% | |
| Q3 2019 | -6.7% | -14.8% | -21.1% | |
| Q2 2019 | -22.0% | -21.2% | +6.8% | |
| Q1 2019 | -22.0% | -21.2% | +6.8% | |
| Q4 2018 | -2.8% | -13.0% | -10.2% | |
| Q3 2018 | +24.2% | +12.1% | +21.2% | |
| Q2 2018 | -31.0% | -54.5% | -86.6% | |
| Q1 2018 | -14.8% | -22.6% | -29.0% | |
| Q4 2017 | -3.0% | +3.8% | +7.8% | |
| Q3 2017 | -4.0% | -9.3% | -6.7% | |
| Q2 2017 | -4.9% | -9.8% | -16.7% | |
| Q1 2017 | +11.6% | +5.4% | +16.1% | |
| Q4 2016 | +5.3% | +2.7% | -13.1% | |
| Q3 2016 | -3.1% | — | — | |
| Q2 2016 | +7.7% | — | — | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +0.0% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — | |
| Q4 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro